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Forkhead box P2 (FOXP2) is a highly conserved transcription factor that has been implicated in human speech and language disorders
and plays important roles in the plasticity of the developing brain. The pattern of nucleotide polymorphisms in FOXP2 in modern
populations suggests that it has been the target of positive (Darwinian) selection during recent human evolution. In our study, we
searched for evidence of selection that might have followed FOXP2 adaptations in modern humans. We examined whether or not
putative FOXP2 targets identified by chromatin-immunoprecipitation genomic screening show evidence of positive selection.We devel-
oped an algorithm that, for any given gene list, systematically generates matched lists of control genes from the Ensembl database,
collates summary statistics for three frequency-spectrum-based neutrality tests from the low-coverage resequencing data of the 1000 Ge-
nomes Project, and determines whether these statistics are significantly different between the given gene targets and the set of controls.
Overall, there was strong evidence of selection of FOXP2 targets in Europeans, but not in the Han Chinese, Japanese, or Yoruba popu-
lations. Significant outliers included several genes linked to cellular movement, reproduction, development, and immune cell traf-
ficking, and 13 of these constituted a significant network associated with cardiac arteriopathy. Strong signals of selection were observed
for CNTNAP2 and RBFOX1, key neurally expressed genes that have been consistently identified as direct FOXP2 targets in multiple
studies and that have themselves been associated with neurodevelopmental disorders involving language dysfunction.Introduction
Humans have adapted in many ways since the split from
chimpanzees around six to seven million years ago, and
some of these adaptations have involved classic selective
sweeps, which leave recognizable signatures in the pattern
of genetic variation surrounding the selected locus.1 There
has been considerable interest in identifying such sweeps,
either by testing individual loci that are considered candi-
dates on the basis of biological insights or by performing
genome scans for identifying selected loci in the absence
of prior knowledge. One complication is that the signa-
tures of positive selection can also arise under neutral con-
ditions, so findings of apparent selection have substantial
but poorly understood false-positive rates.2 As a con-
sequence, evidence of a relevant functional difference
between selected and nonselected alleles is necessary for
high confidence in selection, but such functional evidence
is seldom available.
One gene that has been extensively investigated, both
for genomic patterns indicative of selective sweeps and
in functional studies, is forkhead box P2 (FOXP2 [MIM
605317]) (see Fisher and Scharff3 for a review). This gene
was originally identified from mutations that led to a
dominant Mendelian speech and language disorder in a
three-generation family and in an independent chromo-
somal translocation case.4 Mutations of FOXP2 are rare
but have since been identified in several additional families
affected by speech and language problems.5–7 After human1The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, H
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demonstrated in two ways. First, despite the fact that it
encodes one of the most highly conserved of all vertebrate
proteins (e.g., it is in the top 5% in sequence comparisons
of human-rodent orthologs), two amino acid substitutions
in the region encoded by exon 7 have been fixed on the
human lineage after the split from chimpanzees; this is
significantly more than expected by chance. Second,
resequencing of the FOXP2 genomic locus in a region
adjacent to exon 7 demonstrated a skewed allele frequency
spectrum, suggesting that positive selection most likely
occurred within the last 200,000 years.8 In subsequent
modeling of the human-specific amino acids in mice, alter-
ations in synaptic plasticity and neurite outgrowth9 were
shown to be distinct from those observed in loss-of-func-
tion mouse models,10,11 supporting the idea that these
evolutionary changes might have affected brain develop-
ment. However, analyses of ancient DNA samples
have revealed that the selection detected by the allele-
frequency-spectrum tests was not associated with the
amino acid changes: the amino acid differences were
shared with Neandertals,12 who split from modern
humans 300,000–400,000 years ago, and the haplotypes
extended across the amino acid changes.13
The simplest interpretation of these findings is that
subsequent to the human-chimpanzee split, there have
been at least two successive evolutionary events affecting
the FOXP2 locus. In this view, the first event—the muta-
tions in exon 7—occurred more than ~400,000 years ago,inxton, Cambridge CB10 1SA, UK; 2Language and Genetics Department,
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prior to the human-Neandertal split, and impacted FOXP2
function. The second event, beginning within the last
200,000 years, did not involve further FOXP2 amino acid
changes (because the Neandertal and human FOXP2 are
identical) but might have instead affected FOXP2 noncod-
ing sequences relevant for its expression and/or splicing,
such as the recently described intronic variation that
affects a binding site of pou domain, class 3, transcription
factor 2 (POU3F2 [MIM 600494]).14 These types of cis regu-
latory changes could, for example, have altered regulation
of FOXP2 in a cell type in which it was already expressed or
yielded expression in novel cell types or at developmental
time points when it was previously absent.
FOXP2 is a transcription factor, which directly binds to
DNA and is likely to regulate hundreds of target genes.3
In the present study, we hypothesized that the selective
sweep at FOXP2 within the last 200,000 years might
have been followed by positive selection at some of these
directly regulated targets. The rationale behind this
hypothesis is that FOXP2 function or expression changes
that spread through a population as a result of positive
selection might have exposed its downstream networks
to altered functional landscapes (e.g., different cellular
contexts or developmental time points) and thereby sub-
jected these targets to novel selective pressures.
We developed a pipeline to search for such a pattern of
positive selection downstream of FOXP2 by focusing on
the best candidate-gene targets identified by previous
chromatin-immunoprecipitation (ChIP) genomic screens
(ChIP-chip screens). We have previously calculated
neutrality statistics in 10 kb windows across the genome
from whole-genome sequence data in 179 individuals
from three continental regions.15 These statistics can be
used for assessing the evidence of positive selection at
any locus or group of loci. To do this in a robust fashion,
we developed an algorithm that, for any given gene list
of interest, (1) generates unmatched and matched lists
(n ¼ 1,000) of control genes from the Ensembl database,
(2) collates summary statistics for positive selection from
the 1000 Genomes data, (3) determines whether or
not these summary statistics are significantly different
between the target genes and controls, and (4) identifies
outliers from the gene list as specific candidates for signals
of positive selection. We applied this pipeline to each
of the three sets of putative FOXP2 ChIP targets11,16,17 in
each population.Material and Methods
Data Sets
We calculated genome-wide statistics informative about selection
from low-coverage sequence data in 179 individuals from the pilot
phase of the 1000 Genomes Project: 60 Utah residents with
ancestry from northern andwestern Europe from the CEPH collec-
tion (CEU), 30 Han Chinese from Beijing (CHB), 30 Japanese in
Tokyo, Japan (JPT; combined with CHB as CHB þ JPT), and 59
Yoruba from Ibadan, Nigeria (YRI).15 These statistics were basedThe Amon 10 kb windows and incorporated Tajima’s D,18 Fay and Wu’s
H,19 and Nielsen et al.’s composite likelihood ratio (CLR);20 as
before, the p values from the individual tests were also summa-
rized as a combined p value15 with Fisher’s method for combining
probabilities.21
The gene sets used in the analyses were extracted from the
Ensembl Archives database (Ensembl 54: NCBI Genome browser
build 36), which contains 21,416 protein-coding genes. Removing
X chromosome, Y chromosome, and mitochondrial genes and
those for which there was no recombination data gave a list of
18,486 genes fromwhich the target and control sets were selected.
Three sets of FOXP2 target genes were identified from published
sources11,16,17 and used as input data (Figure S1, available online).
They had been obtained by ChIP-chip screens in a human neuro-
blastoma (SH-SY5Y) cell line,17 embryonic mouse brain,11 and
human fetal brain.16 The initial ChIP-chip efforts for isolating
FOXP2 targets involved partial genomic screens across ~5,000
well-characterized promoters in human fetal brain tissue16 and
in a human neuronal cell line.17 In each case, the authors reported
~300 putative targets enriched by FOXP2 ChIP, and there was
significant overlap between these lists, despite the use of distinct
tissues and different FOXP2 antibodies (Figure S1). Recently, a
systematic large-scale screen of mouse embryonic brain tissue
was carried out; it coupled FOXP2 ChIP to high-density oligonu-
cleotide arrays spanning >17,000 promoters11 and has been the
most comprehensive screen thus far for direct targets of this tran-
scription factor. Notably, the study design (which included a null
mouse as a control) allowed for more robust identification of
targets by using rigorous false-discovery rates (FDRs) and yielded
a shortlist of 264 high-confidence targets, as well as a longer list
of 1,164 candidate targets at a lower stringency.
Ensembl gene IDs were obtained for these gene sets and used as
input files. Genes with no Ensembl ID were excluded. A total of
275/302 FOXP2 targets from the neuronal cell, 263/367 targets
from the human fetal brain, and 207/264 high-confidence genes
from the embryonic mouse brain were used. The mouse brain
target set also excluded 28 genes with no human orthologs and
10 with two or more human-specific paralogs. One study16 also
identified targets in lung tissue, but these were not used.
CNTNAP2 (MIM 604569), a FOXP2 target implicated in speech
and language impairment and identified in another ChIP
study,22 was added to the target lists for human neuronal cells
and the embryonic mouse brain because it has been clearly
validated in both model systems.
Of the 664 FOXP2 targets that were in our gene lists, none were
commonly identified by all three studies. This might be partly
explained by the fact that the earlier studies produced low-strin-
gency sets of ~300 genes from limited screens of defined sections
of 5,000 promoters, whereas the high-confidence gene set from
the embryonic mouse brain came from a much more comprehen-
sive screen (Figure S1). In addition, even when the same gene is
commonly represented on screening arrays of different studies,
the different arrays used do not always survey equivalent regions
of that gene, which means that a true binding event identified in
one study might still be spuriously missed in another. Here, it is
also important to note that ChIP screening studies are quantita-
tive experiments, in which it is necessary to apply some level of
threshold to select for fragments of DNA that are most likely to
be bound by the transcription factor of interest. The two earlier
FOXP2 ChIP studies might have had higher false-positive and
false-negative rates than more recent efforts, but they neverthe-
less uncovered a substantial number of real binding events thaterican Journal of Human Genetics 92, 696–706, May 2, 2013 697
have biological validity. Moreover, it is worth emphasizing
again the use of distinct cell types and species in the various
studies. Finally, given the use of large fragments on the arrays
of the early FOXP2 ChIP studies (as opposed to tiled oligonu-
cleotides in the more recent work), we often lack a clear specifica-
tion of where FOXP2 binds for the targets from those earlier
studies.
Strategy
The analysis pipeline is described in Figure S2. For each of the
three sets of FOXP2 target genes, a matched list of control genes
was generated from the Ensembl Archives database (Ensembl 54:
NCBI Genome browser build 36). FOXP2 targets were matched
with controls in the database for gene length (the longest Ensembl
transcript was taken as representative of gene length), GC con-
tent, and recombination rate (averaged across gene length) esti-
mated from phased haplotypes in the HapMap phase II data
(The International HapMap Consortium 2007; June 25, 2008,
release). This was done by the calculation of Euclidean distances
between each target gene and the remaining protein-coding genes
in the Ensembl gene database on the basis of gene length, GC con-
tent, and average recombination rate and by the generation of
a list of the 1,000 most closely matched genes, i.e., genes that
exhibited the shortest distance from the targets. Subsequently,
for each target set, 1,000 control lists (each containing one closely
matched gene drawn from the 1,000 closest matches for each
gene in the target set) were generated (Figure S2A). The matched
neighbor for each target gene was picked randomly in these
1,000 control lists for the avoidance of systematic error or overrep-
resentation of any particular gene in the control sets. This strategy
was compared with a ranking strategy in which all protein-coding
genes in Ensembl 54 were ranked separately by gene size, GC
content, and average recombination rate, and an average rank
for each gene was obtained. For each gene in the target list, 500
genes above and 500 below its average rank were selected as its
1,000 most closely matched genes and were used in subsequent
analyses.
To test whether FOXP2 target genes show evidence of positive
selection as a group, we carried out statistical assessments by using
the Mann-Whitney U test (on the basis of average ranking of the
test statistics) and permutation tests to see whether Tajima’s D,
Fay and Wu’s H, and Nielsen et al.’s CLR values were significantly
different between the set of FOXP2 target genes and the set of con-
trol genes. For the Mann-Whitney U comparisons, each target set
was compared with 1,000 sets of control genes. Each of these con-
trol sets contained one randomly selected matched Euclidean
‘‘neighbor’’ of each FOXP2 target gene. If the FOXP2 targets were
under positive selection in any of the three populations, the
expectation was that the mean rank of targets would be signifi-
cantly higher for the CLR and significantly lower for Tajima’s D
and Fay and Wu’s H.
Additional support was provided by permutation analyses
carried out on both a single unique list of closely matched ‘‘neigh-
bors’’ generated from the 1,000 control lists and an unmatched
control list that included 18,486 Ensembl 54 genes minus the
target set (Figure S2B). This was a sampled randomization test in
which we computed our statistic, determined a distribution of
this statistic on the basis of 10,000 permutations, and decided
on the significance of our statistic.23
To further gauge the strength of our conclusions about positive
selection in FOXP2 targets, we looked at the distribution of the
enriched genes in the ~5,000 regions identified by genomic scans698 The American Journal of Human Genetics 92, 696–706, May 2, 2as positively selected candidates in the 1000 Genomes Pilot 1
data.15 In order to reduce random background noise, we selected
these regions by a conservative criterion that included only those
with at least two significant ~10 kb windows within a 150 kb
region as outliers. Simulations show that such significant clusters
are indicative of positive selection.24 The significance threshold
was based upon the combined p values estimated from the three
neutrality tests corrected for the 5% FDR in each population
(cutoff p values ¼ 0.00292 for CEU, 0.00262 for YRI, and
0.00216 for CHB þ JPT). We compared 150 kb regions encompass-
ing each gene and treated regions with at least two significant 10
kb windows as indicative of positive selection for genes lying
within this interval. To adjust for size, we sliced genes larger
than 150 kb into 150 kb regions and extended those that were
smaller than 150 kb by an equal distance upstream and down-
stream. The number of FOXP2 target genes identified as significant
outliers with the use of this conservative criterion in each popula-
tion was also compared to the mean number of outliers identified
in 1,000 matched sets of control genes (Figure S3). Significant dif-
ferences in the number of outliers discovered from a matched data
set of similar size were estimated with Fisher’s exact test for count
data in R.
Sequence coverage (per base per gene per individual)
was compared and found to be the same (23–63) across the
FOXP2 targets and controls across all populations (two-sample
Kolmogorov-Smirnov test, p > 0.0925). To exclude a bias from
sequencing errors on site-frequency-based tests of selection, we
compared our Tajima’s D statistic with the Y test specifically
designed for low-coverage data25 that are expected to contain
many artifacts. We generated test statistics for 10 kb nonoverlap-
ping windows for chromosome 11, and the fact that we observed
a significant positive correlation (r2 ¼ 0.94, p value < 0.0001)
between the Y and our Tajima’s D estimates across all populations
(Table S1) indicates that the diversity estimators were not biased
as a result of sequencing errors.
Implementation
The strategy was implemented via a pipeline written with perl and
R commands (available upon request) that were executed on the
Wellcome Trust Sanger Institute ‘‘computer farm’’ with the use
of the Load Sharing Facility job scheduler and the lustre file system
designed to cope with the high throughput. The farm consisted of
a mixture of Intel 23 1.6–3.0 Ghz dual or quad core Xeon EMT64
processors with 4–512 GB of memory and a 64 bit X86_64 linux
operating system.
Ingenuity Pathway Analysis
Ensembl gene identifiers for selected genes were uploaded to
Ingenuity Pathway Analysis (IPA). Networks of these selected
genes were then algorithmically generated on the basis of their
connectivity in the Ingenuity Knowledge Base (IKB), which
includes manually curated data from human, mouse, and rat.
The core analyses tabulate the significance of the association
between the data set and the pathway by (1) estimating a ratio
of the number of data-set genes meeting the expression-value
cutoff and mapping to the pathway to the total number of mole-
cules present in the pathway and (2) using Fisher’s exact test to
calculate a p value determining the probability that the associa-
tion between the genes in the data set and the pathway is
explained by chance alone. The network functional analysis iden-
tified the biological functions and/or diseases that were most
significant to the genes in the network.013
Figure 1. Selection Signals in Gene Sets
of Positive and Negative Controls
The negative log of combined p values for
the matched permutation tests is shown
along the y axis. Known positively selected
gene sets (P) (n ¼ 166, 67, or 31) lie in
regions identified as being under selection
in R7, R8, or 9 genomic scans2 or in a
smaller data set of 11 genes shared among
R7 genomic scans,2 a composite of mul-
tiple signals,22 and the 1000 Genomes
Project.15 Gene lists of negative controls
(N) were generated after exclusion of re-
ported positively selected protein-coding
genes from the Ensembl database. The
dashed horizontal line depicts the thresh-
old for multiple comparisons after applica-
tion of the Bonferroni correction.Results
Establishment of a Pipeline for Detecting Positive
Selection in a Chosen Set of Genes
We first tested our algorithm by using lists of known posi-
tively selected and nonselected genes identified from
reports in the literature.2,15,26 For lists of positive control,
we used data sets containing 166, 67, or 31 genes located
in genomic regions identified as being under positive selec-
tion in R7, R8, or 9 genome-wide scans, respectively,
summarized in Akey,2 and a smaller set of 11 genes shared
between all the studies mentioned above (Figure 1 and
Table S2A). For negative controls, we excluded 2,601
protein-coding genes for which we found any report of
positive selection in the literature and randomly chose
sets of equivalent size from the remaining Ensembl 54
gene set.
The results of the Mann-Whitney U and permutation
tests were in broad agreement (Figure 1 and Table S2) for
these control gene sets. For the known positive-control
gene sets of R31 genes, we observed significant evidence
of selection in CEU and CHB þ JPT, but not in YRI,
probably reflecting the larger number of studies of positive
selection outside Africa and enrichment of non-African
targets. With the smallest set (11 genes), we obtained sig-
nificant combined p values in all three populations.
Gene sets of negative controls did not show any evidence
of positive selection (Figure 1 and Table S2B). We therefore
conclude that our algorithm successfully distinguishes
between positively selected and nonselected groups of
genes.
We estimated the proportion of genes that need to be
under selection in a given target gene list in order for the
target set to be seen as significantly different from the
control set. Frequency-spectrum-based tests had identified
a list of 199 genes that are under selection in all four pop-The American Journal of Humaulations (CEU, CHB, JPT, and YRI)
sequenced at low coverage by the
1000 Genomes Project.15 Gradual
removal and replacement of thesegenes with an equal proportion of negative controls
showed that the method is sensitive if at least 10% of the
genes in a list under investigation are under selection
(Figure S3). The overall size of the list was then reduced.
The pipeline was able to detect a selection signal in all
populations in a list containing at least 50 genes, 10% of
which were known positively selected genes (Figure S4).
Testing Lists of FOXP2 Target Genes for Evidence
of Positive Selection
We then applied the test to the three lists of FOXP2 targets
from the three separate ChIP-chip screens involving
different platforms and neural tissues.11,16,17 In two out
of the three lists, evidence of positive selection was found
in CEU, but not in the other populations (Figure 2 and
Table S3). The two gene sets showing evidence of positive
selection were based on studies of fetal and embryonic
brain tissue in humans and mice, respectively.11,16 Exami-
nation of the test results in more detail revealed that the
support for selection in CEU came both from individual
tests (in mouse brain: Tajima’s D in the Mann-Whitney U
test and Fay and Wu’s H in the matched permutation
test; in human brain: Tajima’s D and Fay and Wu’s H in
the Mann-Whitney U test, Fay and Wu’s H in the matched
permutation test, and CLR and Fay and Wu’s H in the
unmatched permutation test) and from the combined
p values (Table S3). In addition, the Mann-Whitney U tests
showed some evidence of selection in YRI, particularly in
the neuronal cell line, but the combined p value fell below
the threshold for significance after multiple comparisons
in the unmatched permutation results (Figure 2 and
Table S3). Matching target genes by ranks gave similar
results (Figure S5).
In a test variation designed to consider a region of fixed
size larger than individual genes, we compared the number
of 150 kb regions with at least two significant ~10 kbn Genetics 92, 696–706, May 2, 2013 699
Figure 2. Evidence of Positive Selection
in FOXP2 Targets from Three Separate
ChIP-chip Screens
FOXP2 targets identified by ChIP in mouse
and human brain show evidence of
positive selection in CEU. The dashed
horizontal line depicts the threshold of
the –log10p value for multiple comparisons
after application of the Bonferroni correc-
tion. FOXA2 targets identified by ChIP-
Seq do not show enrichment.windows in FOXP2 targets with the number of such re-
gions in 1,000 control lists (Figure S6). FOXP2 targets iden-
tified in embryonic mouse brain were under positive selec-
tion in CEU (p ¼ 0.0341). However, the enrichment was
not significant after correction for multiple comparisons.
FOXA2, another member of the forkhead class of DNA-
binding proteins, was used as an additional negative-
control transcription factor. It was selected from a range
of transcription factors27 because it has not been identified
as being under positive selection in any genomic selection
scans2 and its number of target genes is similar to that of
FOXP2. Compared with matched controls, FOXA2 targets
identified by the ENCODE project28 showed no evidence
of positive selection (Figure 2).
Identification of Individual Genes Showing Evidence
of Positive Selection
Using the combined p values calculated from three
neutrality tests corrected for 5% FDR (e.g., p ¼ 0.00292
for CEU), we identified 67 outlier genes in embryonic
mouse brain and 73 each in human fetal brain and
neuronal cell lines in CEU. CNTNAP2, a key FOXP2 target
that was identified in a separate ChIP study22 and added to
the target lists for human neuronal cells and mouse brain,
was also among these significant outliers. Few of these
genes were shared between populations. The majority
were specific to CEU, in keeping with the strong signal of
selection only in this population (Figure S7).
A total of 139 FOXP2 target genes in human fetal
and mouse embryonic brain stood out as outliers with
strong signals of positive selection in CEU (Table S4).
Thus, in addition to statistical support based on the per-
mutation and Mann-Whitney U tests, there also appears
to be enrichment of positive selection in CEU by this
test. On closer inspection, only two of these targets—
RNA binding protein, fox-1 homolog (RBFOX1 [MIM
605104]) and paraoxonase 2 (PON2 [MIM 602447])—
were shared between the two ChIP-chip screens (see
Discussion). Genes that were under positive selection in
all four HapMap populations included CNTNAP2 and700 The American Journal of Human Genetics 92, 696–706, May 2, 2013another 18 FOXP2 targets identified
in the mouse and human brains
(Table S4).
We also looked at whether the
signature of selection in these 139selected target genes was specifically confined to likely
FOXP2 binding sites on the basis of consensus binding
motifs. We identified FOXP2 (CAAATT), FOX superfamily
consensus (TRTTKRY), and FOXP1 consensus (TATTTRT)
binding motifs within 5 10 kb of the transcription start
site (GENCODE v.2b) of 138/139 selected targets and
observed variants in the FOXP2 binding motifs of 71/139
targets in CEU. Compared with the expected one-third
distribution based on Fisher’s exact test for count data, a
significant enrichment of variation in FOXP2 binding
motifs was found in CEU (p value ¼ 0.002). Fifty-four
variants had a greater frequency in CEU than in YRI and
CHB þ JPT, and in 14/54 instances, the allelic frequency
in CEU was >10% higher than that in YRI and CHB þ
JPT, indicating that these variants could possibly be
responsible for the selection signal observed in this popu-
lation (Table 1).
Properties of Selected FOXP2 Target Genes
The selected CEU FOXP2 target genes are significantly
enriched in nervous system development and function
(such as cell signaling), ion-channel activity, and biological
processes associated with intracellular protein transport
and catabolism. To further categorize the selected CEU
FOXP2 target genes in comparison with the remaining tar-
gets, we used the Database for Annotation, Visualization,
and Integrated Discovery (DAVID v.6.7) but found no addi-
tional significant enrichment of any Gene Ontology (GO)
term associated with any biological process, cellular
compartment, or molecular function.
In another approach to understanding the biological
function of selected genes in CEU, we analyzed them by
using IPA (Ingenuity Systems, Redwood City, CA, USA).
These genes were significantly enriched with molecular
functions associated with cell-to-cell signaling and interac-
tion (p ¼ 1.82 3 106). Of the 73 human brain targets
showing evidence of selection, 72 were designated as
network eligible and 69 were eligible for inclusion in
functional pathways, indicating that they had at least
one functional or disease association in the IKB. The bulk
Table 1. Population Frequencies of Variants in FOXP2 Binding Sites of Genes Selected in the CEU Population
MIM
Number Gene TSS Chr
Variant
Position
Reference
Allele
Alternate
Allele
Ancestral
Allele
Population Frequency (Coverage per
Individual)
CEU CHB þ JPT YRI
604831 EVC 5,763,825 4 5,766,844 G C C 0.23 (53) 0.11 (33) 0.10 (33)
604831 EVC 5,763,825 4 5,769,597 G C C 0.23 (53) 0.11 (33) 0.10 (33)
605035 WASF1 110,536,424 6 110,531,034 T C T 0.69 (53) 0.56 (23) 0.00 (33)
None TP53TG1 86,812,449 7 86,802,732 A C C 0.98 (53) 0.00 (33) 0.80 (33)
613883 KEL 142,348,325 7 142,353,221 T C C 0.91 (53) 0.00 (33) 0.25 (43)
604569 CNTNAP2 145,444,902 7 145,441,261 T C T 0.12 (33) 0.00 (23) 0.00 (13)
122560 CRH 67,251,191 8 67,256,780 G C C 0.93 (53) 0.00 (23) 0.33 (33)
150100 LDHB 21,679,543 12 21,672,448 A G A 0.28 (53) 0.07 (33) 0.06 (33)
607653 RHOJ 62,740,898 14 62,735,721 A C A 0.20 (43) 0.00 (23) 0.00 (23)
607781 PAQR5 67,393,796 15 67,385,180 T A T 0.68 (53) 0.53 (33) 0.48 (33)
601574 TAF15 31,160,596 17 31,154,164 T C C 0.87 (43) 0.64 (23) 0.59 (23)
606411 SLC13A3 44,619,870 20 44,614,848 A G G 0.18 (73) 0.04 (43) 0.05 (43)
606411 SLC13A3 44,647,744 20 44,653,243 C T C 0.13 (43) 0.00 (23) 0.00 (23)
146770 IGLL1 22,245,312 22 22,247,949 T C - 0.97 (53) 0.00 (43) 0.70 (33)
Abbreviations are as follows: TSS, transcription start site; and Chr, chromosome.of these were represented in networks associated with
cellular movement, hematological system development,
and function and immune cell trafficking (35 genes). Of
the 68 mouse brain targets showing evidence of selection,
one could not be mapped to human reference build
GRCh37 (UCSC Genome Browser hg19), on which the
IKB is based. Of the remaining targets, 65 were network
eligible and 55 were eligible for inclusion in functional
pathways, and the bulk were represented by four networks
associated with DNA replication, recombination, and
repair (20 genes), cell-to-cell signaling and interaction
(18 genes), nervous system development (14 genes), and
cardiovascular system development and function (12
genes). Intriguingly, for both CEU-enriched data sets, the
only significant pathological network (Figure 3) consisted
of 13 genes associated with cardiac arteriopathy (p ¼
0.009 and 0.004 for the human and mouse brain targets,
respectively). RBFOX1 and CNTNAP2 are both part of
this network (Figure S8), and both have been linked to
brain development and function.Discussion
We set out to explore whether recent positive selection on
FOXP2 was followed by selection in any of the known
target genes that it directly regulates.
We developed a general methodology to systematically
scan gene lists for evidence of positive selection acting
on a gene set as a whole. A key part of this method is to
match candidate genes with controls for gene length, GCThe Amcontent, and recombination rate and compare three
summary statistics—Tajima’s D,18 Fay and Wu’s H,19 and
a CLR20—for each nonoverlapping ~10 kb window across
the genome by using the low-coverage resequencing data
generated by the 1000 Genomes Project.15 The procedure
was validated with the use of test sets of known positively
selected genes identified by genome-wide scans for selec-
tion.2,15,26 It has been shown that regions identified in
genotype-based (LD-based) genome scans for positive
selection are also picked up by frequency-spectrum-based
tests on resequencing data,24 so we would expect these to
act as useful positive controls in our analysis. Although
the majority of these genes do not have independent func-
tional evidence of selection, these reduced sets represent
the best candidates available for positive selection. In all,
we conclude that our method is robust in distinguishing
between selected and nonselected gene sets as small as 11.
Levels of overlap among the top FOXP2 targets reported
by all three ChIP-chip screens were rather low (Figure S1).
No targets were shared across all three gene lists used in our
study, and only a minority of targets were common to two
of the prior reports. The limited overlap is partly attribut-
able to methodological and tissue differences in the three
ChIP-chip studies (see Material and Methods for a more
detailed explanation). The earlier surveys16,17 used micro-
arrays containing a relatively small subset of known pro-
moter regions, whereas Vernes et al.11 employed a much
more comprehensive screen with tiled oligonucleotides
across the majority of promoters of the genome. Thus, a
large number of the genes and regulatory regions queried
by the Vernes et al. study11 had not been examined inerican Journal of Human Genetics 92, 696–706, May 2, 2013 701
Figure 3. IPA of FOXP2 Targets Identi-
fied as Significant Outliers in CEU Shows
Significant Association with Cardiac Arte-
riopathythe earlier studies. As well as performing a screen with a
larger scope, the latter investigation was able to employ
more rigorous controls for assessing significance, yielding
a high confidence list with a particularly low FDR
(although it is clear from validation experiments that the
earlier studies did include a substantial number of true pos-
itive findings). Moreover, differences in the top putative
targets highlighted in each set of experiments might
have resulted from differences in biological material:
Vernes et al.16 used human neuron-like cell lines, Spiteri
et al.15 assessed human fetal brain tissue, and Vernes
et al.11 screened mouse embryonic brain. ChIP followed
by next-generation sequencing (ChIP-seq) technology29
in multiple different neural tissue samples might provide
a more robust set of FOXP2 targets for re-evaluation.
Overall, there is strong evidence of selection of FOXP2
targets in CEU compared with YRI and CHB þ JPT. In
CEU, with a matched and unmatched data set, we were
able to consistently pick up significant differences between
controls and human fetal brain FOXP2 targets by using a
stringent Bonferroni correction cutoff. If selection had
occurred in all populations and we were able to detect it
in CEU, we should also have been able to detect it in
Africans (YRI) because of their larger effective population
size. The fact that we did not detect a signal in Africans
indicates that selection was regionally specific and, among
the populations examined, acted only in the Europeans
(CEU). Part of the explanation might be the higher quality
of the CEU data, but we did not observe any differences
in the coverage between the targets and their matched
controls.
Significant differences between controls and FOXP2
targets identified in mouse brain tissue were also observed,
but these were less consistent. Overall, no significant
differences were observed between controls and FOXP2
targets identified in the neuronal cell line in any of the
populations, although there was weak evidence of selec-
tion in YRI according to the comparisons with matched
controls. This cell line was established from a metastatic
neuroblastoma from a 4-year-old girl whose ethnicity was
unknown.30702 The American Journal of Human Genetics 92, 696–706, May 2, 2013The strongest support was for
human fetal brain FOXP2 targets in
CEU (Figure 2). These results were
also reinforced by the presence of
more outlier FOXP2 targets in CEU
(n ¼ 110) compared to CHB þ JPT
(n ¼ 40) and YRI (n ¼ 79) and by
the identification of variants present
in FOXP2 binding sites of 71 genes
selected in CEU. Fifty-four of thesevariants were present at a higher frequency in CEU, and
14 had a >10% higher frequency in this population (Table
1), making them prime candidates for functional studies.
However, it must be emphasized that our hypothesis of se-
lection acting on FOXP2 targets does not assume that this
must have happened specifically at the genomic sites
where FOXP2 directly binds and only involved changes
to DNA sequences within those binding sites. Rather, we
are testing the more general idea that, after the selective
sweep at FOXP2, some of the genes in networks down-
stream of FOXP2 became subject to further recent selec-
tion, which might have involved any parts of those genes.
To understand what this means in biological terms, we
examined the brain outlier FOXP2 targets (from the data
sets for the human fetal brain andmouse embryonic brain)
in CEU. The majority of selected FOXP2 targets (~52%)
were specific to this population group, and fewwere shared
between two or among all three populations, suggesting
that the signal stems primarily from recent local adapta-
tion after the divergence of the populations. CNTNAP2, a
FOXP2 target that has itself been implicated in speech
and language impairment and development,22,31 was the
one target that also stood out as a significant outlier in
all populations (Figure S9). FOXP2 binds to a regulatory
sequence in intron 1 of CNTNAP2 and decreases its expres-
sion.22 Variants in this gene have also been implicated in
several neurological phenotypes, including autism spec-
trum disorders,32,33 but the fact that the selection signal
overlies a substantial portion of this large gene makes it
difficult to assess the critical functional variant responsible
for the selection signal. Genes showing evidence of selec-
tion in all populations are of particular interest for they
provide insights into the selection pressures that have
acted on all populations, and because these have been
replicated in different sequence data sets, the signals are
more likely to be reliable.
PON2 and RBFOX1 are two other FOXP2 targets, identi-
fied in multiple experiments and tissues (mouse and
human brains), that show evidence of selection. RBFOX1
and CNTNAP2 are also among the FOXP2 target genes
that belong to an IPA network involved in cardiac
Figure 4. Genes under Selection in CEU
(A) A chromosome 19 gene-rich region that harborsGGN. The signal is sustained over several 10 kb windows that also encompass nearby
genes SPRED3 and FAM98C, which could also be the target of selection.
(B) Another chromosome 19 region that harbors PVR. In both parts, tracks showing DNase clusters and FOXP2 binding sites determined
by ChIP-Seq (ENCODE data from the HudsonAlpha Institute for Biotechnology) in two neural cell lines (PFSK-1 and SK-N-MC) provide
additional support for the direct FOXP2 binding (bands) within this region. These represent enriched regions of high read density rela-
tive to total input chromatin control reads in the ChIP experiment. FOXP2 binding sites are observed in both cell lines in (A) but only in
SK-N-MC in (B). The dbSNP (135) track shows variants identified in this region. The coding nonsynonymous and essential-splice-site
variants are represented by vertical red lines, and coding synonymous variants are represented by vertical green lines. The –log10p of
the combined p value (boxed area) was generated from the separate probabilities of Tajima’s D, Fay andWu’s H, and CLR. The threshold
represented by the dashed line incorporates the 5% FDR for each population. Peaks above the threshold in the graph represent regions
under positive selection in CEU.
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arteriopathy (Figure 3 and Figure S5). PON2 encodes a
high-density-lipoprotein-related glycoprotein with multi-
enzymatic and antioxidant properties.34 Variants in this
gene have also been associated with the severity of coro-
nary artery disease.35,36 RBFOX1 is predominantly ex-
pressed in muscle and brain tissue and regulates tissue-spe-
cific splicing.37 Like CNTNAP2, RBFOX1 has also been
implicated in autism spectrum disorders,38 and a selection
signal is apparent in all populations examined.
Genes showing evidence of selection in single popula-
tions should be interpreted with more caution because
they could be false positives or show signals resembling
selection as a result of genetic drift. Nevertheless, there
are some interesting targets that appear to be selected
solely in CEU. In this population, 65% of the selected
FOXP2 targets were identified in the human and mouse
brain studies. Targets that are of interest from an
evolutionary perspective include BRCA1-associated
RING domain 1 (BARD1 [MIM 601593]), which plays a
role in apoptosis; epiphycan (EPYC [MIM 601657]),
which is involved in bone and cartilage formation;39
cation channel, sperm-associated 3 (CATSPER3 [MIM
609120]), encoding a voltage-gated calcium-channel pro-
tein that is essential for successful fertilization;40 gameto-
genetin (GGN [MIM 609966]), which plays a role in sper-
matogenesis;41 and polio virus receptor (PVR [MIM
173850]) (Figure 4). The selection signal around GGN is
sustained over several 10 kb windows that also encom-
pass nearby genes SPRED3 (MIM 609293) and FAM98C,
which could also be the target of selection. The dN/dS
ratios for GGN comparisons between humans and chim-
panzees and humans and orangutans are 1.43 and 1.32,
respectively, and there is an unusual cluster of nonsynon-
ymous coding mutations in GGN (Figure 4A); one such
mutation (rs11083455) has a high frequency (0.91) in
Europeans.
One advantage of this methodology is that it can be
applied to any chosen set of genes or protein-interaction
networks without any a priori hypothesis about the cause
of selection. Kim et al.42 suggest that protein networks
intuitively hold much more evolutionary information
than do lists derived from GO and genome-wide associa-
tion studies, which do not distinguish between con-
strained core and peripheral proteins that are potentially
under positive selection. Such unbiased comparisons will
identify genes that might be relevant for evolutionary
adaptations and narrow down candidates for functional
follow-up.
The availability of large-scale whole-genome human
population sequences through the efforts of projects
such as the 1000 Genomes Project15 will make this a prac-
tical approach for high-throughput screening of selection
signals associated with local adaptations in these popula-
tions, for which the present FOXP2 study has provided a
development and test opportunity. We found strong
evidence of selection for some FOXP2 targets in CEU for
some aspects of development, cell signaling, reproduction,704 The American Journal of Human Genetics 92, 696–706, May 2, 2or immunity. The selected genes often have multiple func-
tions in both neural and nonneural tissues.Supplemental Data
Supplemental Data include nine figures and four tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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